Gene and cell therapies are now providing patients with treatments for many traditionally incurable diseases. These clinical successes are likely to be just the tip of the iceberg—the full promise of this field is yet to be realized. Pharmaceutical companies are therefore investing heavily in R&D to develop new products, with a surge of gene and cell therapy agents now entering early development.
Although academic-industry collaboration models are proving successful in many cases, their development is not without challenges. Fundamentally, academic and industry institutions have evolved starkly different cultures that challenge successful collaboration. Here, I will highlight three challenges to the success of academic-industry collaboration and offer ideas to overcome them.
The recent explosive growth of the biologics sector looks set to continue and their therapeutic use is increasingly being recognized as a fourth major method in cancer therapy (alongside the well-established approaches of surgery, chemotherapy and radiotherapy). With their suitability for individualized treatment, biologics will also play a key role in the development of precision medicine, another major area of focus for researchers, healthcare providers, investors and pharmaceutical companies. To predict and fully leverage the potential of biologics, it is important to understand the intricacies of this complex market.
Successful scientists must be able to convincingly explain their research, be able to differentiate themselves in a sea of funding applications and speak confidently about their research to other scientists and non-scientists. These skills are not always emphasized in the academic environment, but are necessary to establish and run a successful research team.
Patent applications are frequently rejected. In fact, more often than not, your patent claims will be denied at the first attempt. These rejections can be costly and time-consuming, so a way to minimize their occurrence is highly sought-after. Fortunately, there are approaches you can take to streamline the application process and help put your best foot forward from the beginning. Here, we’ll showcase some of the common pitfalls that R&D companies encounter with patent applications and highlight the best approaches you can take to increase the chances of getting your patent granted.
Read on to see what key benefits CAS marketing is attributing to Agile less than one year in on our journey, as well as some lessons we have learned along the way that your teams may want to consider if they are embarking on or optimizing an Agile practice.
Whatever your research goals, it's absolutely essential that you know your field inside out to maximize the value of your work. Whether you're competing for government grant funding, investor backing or internal investment within a large R&D organization, you need to be able to effectively make your case with current information.